The global human microbiome analysis market was valued at USD 1.24 billion in 2025. The market is estimated at USD 1.39 billion in 2026 and is projected to reach USD 4.21 billion by 2036, at a CAGR of 11.7% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering sequencing and multi-omics technologies, sample handling, bioinformatics and AI, research, clinical, and consumer testing, regulation, the therapeutics pipeline, pricing, the supplier landscape, and future growth opportunities.
The market covers the services, consumables, instruments, and software that laboratories use to profile the makeup and activity of microbes living in the gut, mouth, skin, vaginal and urogenital tract, and airways. It includes collection and stabilization kits, extraction and library preparation kits, microbial reference standards, sequencers and other instruments for 16S rRNA, shotgun metagenomic, metatranscriptomic, and qPCR work, taxonomic and functional profiling software, and research sequencing, clinical testing, and consumer testing services. Microbiome therapeutics, probiotics, and prebiotics themselves, clinical pathogen identification and infectious disease diagnostics, and environmental, agricultural, and animal microbiome analysis are excluded.
VOWST, created by Seres Therapeutics and later acquired by Nestlé Health Science, became the first orally administered microbiome-based therapy approved by the FDA, indicated to help prevent the return of Clostridioides difficile infection in adults, and Nestlé Health Science struck a June 2026 deal to pay USD 25 million in exchange for ending possible future sales-based milestones. In clinical testing, Microba Life Sciences reported fiscal year 2026 core testing revenue of AUD 9.0 million, up 92%, on 22,418 tests, a 78% increase, and an annualized fourth-quarter run rate of more than 25,000 tests in its Australian and U.K. markets.
Sample collection, storage, extraction, sequencing, and bioinformatics methods vary widely, and these differences can change the apparent makeup of a microbial community, which limits comparison across studies and confidence in clinical results. Many tests lack clinical validation and payer coverage, so patients often pay out of pocket. Much of the evidence is still associative, and individual variation driven by diet, medication, and geography makes consistent disease signatures hard to define. Therapeutics developers also face funding strain; Seres Therapeutics reported holding USD 29.8 million in cash as of March 31, 2026, enough to fund operations only into early 2027.
Microbiome biomarkers in immuno-oncology and wider drug development are a significant opportunity, as gut microbes affect drug metabolism, efficacy, toxicity, and immune response and drug makers are adding microbiome sampling to trials; SER-155 is also being studied in checkpoint inhibitor-related enterocolitis. Multi-omics work that links metagenomics with metatranscriptomics, metabolomics, and host genomics, vaginal, oral, and skin applications, and AI models that find disease signatures and predict diet response offer further openings. Key trends include the move from 16S to shotgun and long-read metagenomics, a sharper focus on reference standards, highlighted by Zymo Research at ASM Microbe 2026, and growth in clinical and consumer gut health testing.
By offering, the human microbiome analysis market is segmented into services, kits & reagents, instruments, and software & bioinformatics. Services span research, clinical, and consumer testing, and kits & reagents span sample collection, extraction, and library kits and reference standards. Services are expected to hold the largest share in 2026, as academic groups, drug and therapeutics developers, and food companies outsource sequencing and analysis rather than build in-house capability, and clinical and consumer testing volumes are climbing, as Microba's results show. Software & bioinformatics is projected to record the highest CAGR, driven by ever larger shotgun and multi-omics datasets, demand for consistent profiling of which microbes are present and what they do, and the uptake of AI interpretation. Kits & reagents should also grow strongly as standardized collection kits and reference standards gain use.
By technology, the human microbiome analysis market is segmented into 16S rRNA gene sequencing, shotgun metagenomic sequencing, metatranscriptomics & multi-omics, qPCR, and other technologies. 16S rRNA gene sequencing leads in 2026, given its low cost, mature protocols, and wide use in large research studies. Shotgun metagenomic sequencing is set to grow the fastest, supported by falling sequencing costs, demand for species-, strain-, and gene-level detail that 16S cannot provide, and its adoption in clinical tests such as Microba's. Metatranscriptomics & multi-omics should grow strongly from a smaller base as studies shift toward microbial function.
By sample type, the human microbiome analysis market is segmented into gut & fecal, oral, skin, vaginal & urogenital, respiratory, and other samples. Gut & fecal samples account for the largest share in 2026, since the gut microbiome is the main focus of research, clinical and consumer testing, and therapeutics development, including therapies for C. difficile infection and inflammatory bowel disease. Vaginal & urogenital samples are projected to record the highest CAGR, driven by research on the vaginal microbiome's role in reproductive health, pregnancy outcomes, and infections and by new diagnostics and therapies in this area. Low microbial biomass in skin and respiratory samples favors providers with validated site-specific kits.
By application, the human microbiome analysis market is segmented into disease & translational research (gastrointestinal, metabolic, immune & inflammatory, oncology, neurological, and infectious diseases), drug discovery & development, clinical diagnostics, consumer wellness & personalized nutrition, and other applications. Disease & translational research holds the largest share in 2026, reflecting heavy use of microbiome analysis in gastroenterology, immunology, metabolism, oncology, and neuroscience research. Clinical diagnostics is set to grow the fastest, supported by rising clinical metagenomic testing, new products such as Microba's GI Navigator planned for September 2026, and a growing evidence base for microbiome-guided care. Drug discovery & development is also expected to grow strongly on therapeutics programs and immuno-oncology biomarkers.
By end user, the human microbiome analysis market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinical laboratories, food, nutrition & consumer health companies, and other end users. Academic & research institutes hold the largest share in 2026, as universities and research institutes carry out a large share of microbiome research. Hospitals & clinical laboratories are projected to grow the fastest, as clinical microbiome tests enter routine use and analysis supports transplant, oncology, and gastroenterology care. Food, nutrition, and probiotic companies use analysis to develop and support product claims, and Microba said its PHGG prebiotic fiber sold more than twice as many units in its fiscal 2026 fourth quarter.
North America is expected to hold the largest share of the global human microbiome analysis market in 2026, supported by strong research funding, many academic microbiome centers, a concentration of therapeutics developers and drug companies, the commercial launch of the first FDA-approved microbiome therapies, and providers such as Illumina, Thermo Fisher Scientific, PacBio, Zymo Research, and CosmosID. Clinical programs such as SER-155 add demand for clinical-grade analysis, and Canada contributes through academic research.
Asia-Pacific is projected to grow at the highest CAGR, driven by expanding research, large and diverse populations, rising metabolic and digestive disease, and consumer interest in gut health and functional foods. China is expected to lead the region, supported by large research programs and service providers such as Novogene, Japan and South Korea are expected to grow strongly on functional food, probiotic, and research activity, and Australia, home to Microba, is a key market for clinical metagenomic testing. Europe holds a significant share, backed by academic research, large cohort studies, and food, nutrition, and drug companies investing in the microbiome; the U.K. is a key country for clinical and consumer tests and hosts Oxford Nanopore Technologies, while France, Germany, the Netherlands, Belgium, Denmark, and Ireland host research centers and probiotic companies. Latin America, with research in Brazil and Mexico, and the Middle East & Africa, with precision medicine investment in Saudi Arabia, the UAE, and Israel, account for smaller shares.
Sequencing platform suppliers, kit and reagent makers, research service laboratories, clinical and consumer testing companies, and bioinformatics firms all compete in the fragmented human microbiome analysis market across research, clinical, and consumer segments. Companies compete on analytical resolution, reproducibility, speed, price per sample, databases and analysis tools, clinical evidence, and the capacity to handle large studies. Leading players are building standardized collection and extraction workflows, reference standards, shotgun and long-read solutions, multi-omics services, clinical tests, and AI analysis platforms. Recent developments include Zymo Research's showcase of microbial community standards and multi-omics services at ASM Microbe 2026, Microba's strong testing growth in fiscal 2026 and its planned GI Navigator launch, and Nestlé Health Science's June 2026 buyout of VOWST sales milestones from Seres Therapeutics.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), Zymo Research Corporation (U.S.), Microba Life Sciences Limited (Australia), CosmosID, Inc. (U.S.), and Novogene Co., Ltd. (China).
The market covers the services, consumables, instruments, and software that laboratories use to profile the makeup and activity of microbes living in the gut, mouth, skin, vaginal and urogenital tract, and airways. It includes collection and stabilization kits, extraction and library preparation kits, microbial reference standards, sequencers and other instruments for 16S rRNA, shotgun metagenomic, metatranscriptomic, and qPCR work, taxonomic and functional profiling software, and research sequencing, clinical testing, and consumer testing services. Microbiome therapeutics, probiotics, and prebiotics themselves, clinical pathogen identification and infectious disease diagnostics, and environmental, agricultural, and animal microbiome analysis are excluded.
VOWST, created by Seres Therapeutics and later acquired by Nestlé Health Science, became the first orally administered microbiome-based therapy approved by the FDA, indicated to help prevent the return of Clostridioides difficile infection in adults, and Nestlé Health Science struck a June 2026 deal to pay USD 25 million in exchange for ending possible future sales-based milestones. In clinical testing, Microba Life Sciences reported fiscal year 2026 core testing revenue of AUD 9.0 million, up 92%, on 22,418 tests, a 78% increase, and an annualized fourth-quarter run rate of more than 25,000 tests in its Australian and U.K. markets.
Market Dynamics
Demand in the human microbiome analysis market is led by a growing body of research tying microbial communities to bowel disorders, C. difficile infection, obesity, type 2 diabetes, heart disease, allergic, autoimmune, and neurological conditions, and response to cancer immunotherapy, which has made microbiome sampling a routine part of large cohort studies and trials. Developers of live biotherapeutics rely on analysis to pick targets, select patients, confirm engraftment, and find response biomarkers, and Seres is developing SER-155, which holds Breakthrough Therapy and Fast Track designations for allogeneic stem cell transplant patients. Metagenomic gut tests that support assessment of digestive conditions and guide diet and treatment are gaining clinical use, while cheaper shotgun and long-read sequencing from providers such as PacBio and Oxford Nanopore Technologies makes strain-level, functional, and full-length 16S analysis affordable.Sample collection, storage, extraction, sequencing, and bioinformatics methods vary widely, and these differences can change the apparent makeup of a microbial community, which limits comparison across studies and confidence in clinical results. Many tests lack clinical validation and payer coverage, so patients often pay out of pocket. Much of the evidence is still associative, and individual variation driven by diet, medication, and geography makes consistent disease signatures hard to define. Therapeutics developers also face funding strain; Seres Therapeutics reported holding USD 29.8 million in cash as of March 31, 2026, enough to fund operations only into early 2027.
Microbiome biomarkers in immuno-oncology and wider drug development are a significant opportunity, as gut microbes affect drug metabolism, efficacy, toxicity, and immune response and drug makers are adding microbiome sampling to trials; SER-155 is also being studied in checkpoint inhibitor-related enterocolitis. Multi-omics work that links metagenomics with metatranscriptomics, metabolomics, and host genomics, vaginal, oral, and skin applications, and AI models that find disease signatures and predict diet response offer further openings. Key trends include the move from 16S to shotgun and long-read metagenomics, a sharper focus on reference standards, highlighted by Zymo Research at ASM Microbe 2026, and growth in clinical and consumer gut health testing.
Segment Analysis
The report analyzes the market by offering, technology, sample type, application, end user, and geography, helping stakeholders identify the most attractive growth areas.By offering, the human microbiome analysis market is segmented into services, kits & reagents, instruments, and software & bioinformatics. Services span research, clinical, and consumer testing, and kits & reagents span sample collection, extraction, and library kits and reference standards. Services are expected to hold the largest share in 2026, as academic groups, drug and therapeutics developers, and food companies outsource sequencing and analysis rather than build in-house capability, and clinical and consumer testing volumes are climbing, as Microba's results show. Software & bioinformatics is projected to record the highest CAGR, driven by ever larger shotgun and multi-omics datasets, demand for consistent profiling of which microbes are present and what they do, and the uptake of AI interpretation. Kits & reagents should also grow strongly as standardized collection kits and reference standards gain use.
By technology, the human microbiome analysis market is segmented into 16S rRNA gene sequencing, shotgun metagenomic sequencing, metatranscriptomics & multi-omics, qPCR, and other technologies. 16S rRNA gene sequencing leads in 2026, given its low cost, mature protocols, and wide use in large research studies. Shotgun metagenomic sequencing is set to grow the fastest, supported by falling sequencing costs, demand for species-, strain-, and gene-level detail that 16S cannot provide, and its adoption in clinical tests such as Microba's. Metatranscriptomics & multi-omics should grow strongly from a smaller base as studies shift toward microbial function.
By sample type, the human microbiome analysis market is segmented into gut & fecal, oral, skin, vaginal & urogenital, respiratory, and other samples. Gut & fecal samples account for the largest share in 2026, since the gut microbiome is the main focus of research, clinical and consumer testing, and therapeutics development, including therapies for C. difficile infection and inflammatory bowel disease. Vaginal & urogenital samples are projected to record the highest CAGR, driven by research on the vaginal microbiome's role in reproductive health, pregnancy outcomes, and infections and by new diagnostics and therapies in this area. Low microbial biomass in skin and respiratory samples favors providers with validated site-specific kits.
By application, the human microbiome analysis market is segmented into disease & translational research (gastrointestinal, metabolic, immune & inflammatory, oncology, neurological, and infectious diseases), drug discovery & development, clinical diagnostics, consumer wellness & personalized nutrition, and other applications. Disease & translational research holds the largest share in 2026, reflecting heavy use of microbiome analysis in gastroenterology, immunology, metabolism, oncology, and neuroscience research. Clinical diagnostics is set to grow the fastest, supported by rising clinical metagenomic testing, new products such as Microba's GI Navigator planned for September 2026, and a growing evidence base for microbiome-guided care. Drug discovery & development is also expected to grow strongly on therapeutics programs and immuno-oncology biomarkers.
By end user, the human microbiome analysis market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinical laboratories, food, nutrition & consumer health companies, and other end users. Academic & research institutes hold the largest share in 2026, as universities and research institutes carry out a large share of microbiome research. Hospitals & clinical laboratories are projected to grow the fastest, as clinical microbiome tests enter routine use and analysis supports transplant, oncology, and gastroenterology care. Food, nutrition, and probiotic companies use analysis to develop and support product claims, and Microba said its PHGG prebiotic fiber sold more than twice as many units in its fiscal 2026 fourth quarter.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 19 countries and four rest-of-region groups. The regional analysis considers research funding, therapeutics development, testing adoption, food and probiotic industries, and local suppliers.North America is expected to hold the largest share of the global human microbiome analysis market in 2026, supported by strong research funding, many academic microbiome centers, a concentration of therapeutics developers and drug companies, the commercial launch of the first FDA-approved microbiome therapies, and providers such as Illumina, Thermo Fisher Scientific, PacBio, Zymo Research, and CosmosID. Clinical programs such as SER-155 add demand for clinical-grade analysis, and Canada contributes through academic research.
Asia-Pacific is projected to grow at the highest CAGR, driven by expanding research, large and diverse populations, rising metabolic and digestive disease, and consumer interest in gut health and functional foods. China is expected to lead the region, supported by large research programs and service providers such as Novogene, Japan and South Korea are expected to grow strongly on functional food, probiotic, and research activity, and Australia, home to Microba, is a key market for clinical metagenomic testing. Europe holds a significant share, backed by academic research, large cohort studies, and food, nutrition, and drug companies investing in the microbiome; the U.K. is a key country for clinical and consumer tests and hosts Oxford Nanopore Technologies, while France, Germany, the Netherlands, Belgium, Denmark, and Ireland host research centers and probiotic companies. Latin America, with research in Brazil and Mexico, and the Middle East & Africa, with precision medicine investment in Saudi Arabia, the UAE, and Israel, account for smaller shares.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025. Company profiles include business and financial overviews, microbiome analysis portfolios, product portfolios, strategic developments, and SWOT analyses.Sequencing platform suppliers, kit and reagent makers, research service laboratories, clinical and consumer testing companies, and bioinformatics firms all compete in the fragmented human microbiome analysis market across research, clinical, and consumer segments. Companies compete on analytical resolution, reproducibility, speed, price per sample, databases and analysis tools, clinical evidence, and the capacity to handle large studies. Leading players are building standardized collection and extraction workflows, reference standards, shotgun and long-read solutions, multi-omics services, clinical tests, and AI analysis platforms. Recent developments include Zymo Research's showcase of microbial community standards and multi-omics services at ASM Microbe 2026, Microba's strong testing growth in fiscal 2026 and its planned GI Navigator launch, and Nestlé Health Science's June 2026 buyout of VOWST sales milestones from Seres Therapeutics.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), Zymo Research Corporation (U.S.), Microba Life Sciences Limited (Australia), CosmosID, Inc. (U.S.), and Novogene Co., Ltd. (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global human microbiome analysis market.
- Explains how disease research, microbiome therapeutics, and clinical and consumer testing are shaping demand.
- Assesses the impact of workflow variability, limited clinical validation and reimbursement, and funding pressure on therapeutics developers.
- Identifies high-growth opportunities across offering, technology, sample type, application, end user, and region.
- Tracks shotgun and long-read metagenomics, multi-omics, reference standards, and AI-based interpretation.
- Benchmarks leading platform, kit, service, and testing companies by portfolio and strategic developments.
- Supports product planning, partnering, and market entry decisions for suppliers, test developers, and investors.
Key Questions Answered
- How big is the global human microbiome analysis market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How quickly are users replacing 16S sequencing with shotgun, long-read, and multi-omics methods?
- How are microbiome therapeutics and immuno-oncology biomarkers changing demand for clinical-grade analysis?
- Which offering, technology, sample type, application, and end-user segments will grow the fastest?
- What standardization and validation steps are needed for wider clinical use of microbiome tests?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and how do they compare on technology and services?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Human Microbiome Analysis Market, by Offering
6. Human Microbiome Analysis Market, by Technology
7. Human Microbiome Analysis Market, by Sample Type
8. Human Microbiome Analysis Market, by Application
9. Human Microbiome Analysis Market, by End User
10. Human Microbiome Analysis Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
- Zymo Research Corporation
- Microba Life Sciences Limited
- CosmosID, Inc.
- Novogene Co., Ltd.
